Dr. Paul R. Eber, M.D.
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,398
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
TN license 20950 · MS license 18433
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
- Baptist Memorial Hospital Memphis, TN
- Baptist Memorial Hospital Tipton Covington, TN
Medical groups
- Conrad Pearson Clinic PC (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,398
- Services billed
- 71,074
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, testosterone cypionate, 1 mg | 37,019 | 36 |
| Injection, denosumab, 1 mg | 16,380 | 51 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 9,300 | 112 |
| Injection, medroxyprogesterone acetate, 1 mg | 4,950 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,010 | 1,133 |
| Insertion of needle into vein for collection of blood sample | 1,849 | 863 |
| Psa (prostate specific antigen) measurement, total | 1,695 | 783 |
| Manual urinalysis test with examination using microscope, automated | 1,689 | 1,085 |
| Creatinine level to test for kidney function or muscle injury | 1,686 | 1,083 |
| Testosterone (hormone) level, total | 896 | 232 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 727 |
| Tamsulosin Hcl Other prescribers in Germantown, TN | 662 |
| Erleada (apalutamide) | 436 |
| Nubeqa (darolutamide) | 203 |
| Dutasteride Other prescribers in Germantown, TN | 162 |
| Prednisone Other prescribers in Germantown, TN | 149 |
| Xtandi (enzalutamide) | 149 |
| Finasteride Other prescribers in Germantown, TN | 135 |
| Abiraterone Acetate | 131 |
| Cephalexin Other prescribers in Germantown, TN | 124 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 123 payments worth $70,588 in total to this clinician.
| Janssen Biotech, Inc. | $24,492 |
|---|---|
| Dendreon Pharmaceuticals LLC | $21,279 |
| Astellas Pharma US Inc | $14,645 |
| Bayer HealthCare Pharmaceuticals Inc. | $4,837 |
| Avyxa Pharma, LLC | $3,371 |
| Ferring Pharmaceuticals Inc. | $311 |
| Sumitomo Pharma America, Inc. | $279 |
| Urogen Pharma, Inc. | $270 |
| Compensation for services other than consulting (speaking, faculty) | $60,835 |
|---|---|
| Travel and Lodging | $6,742 |
| Food and Beverage | $2,976 |
| Education | $35.06 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC Mar 1, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $6,300 |
| Dendreon Pharmaceuticals LLC Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $4,550 |
| Dendreon Pharmaceuticals LLC Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $4,550 |
| Astellas Pharma US Inc Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $4,550 |
| Janssen Biotech, Inc. Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $3,902 |
| Astellas Pharma US Inc Jun 21, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $3,900 |
All 44 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
| Janssen Biotech, Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,110 |
| Dendreon Pharmaceuticals LLC Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $4,550 |
| Dendreon Pharmaceuticals LLC Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $508 |
| Dendreon Pharmaceuticals LLC Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $180 |
| Dendreon Pharmaceuticals LLC Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $73.34 |
| Janssen Biotech, Inc. Oct 21, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Panama City, FL · in-kind | $769 |
| Janssen Biotech, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 13, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Panama City, FL · in-kind | $5.50 |
| Janssen Biotech, Inc. Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $3,902 |
| Janssen Biotech, Inc. Sep 9, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Panama City, FL · in-kind | $299 |
| Astellas Pharma US Inc Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $4,550 |
| Astellas Pharma US Inc Aug 26, 2025 | Travel and Lodging Xtandi · Oncology · travel to Independence, OH | $631 |
| Astellas Pharma US Inc Aug 26, 2025 | Travel and Lodging Xtandi · Oncology · travel to Independence, OH | $505 |
| Astellas Pharma US Inc Aug 26, 2025 | Travel and Lodging Xtandi · Oncology · travel to Independence, OH | $229 |
| Janssen Biotech, Inc. Aug 15, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Baton Rouge, LA | $157 |
| Janssen Biotech, Inc. Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Aug 4, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Jonesboro, AR | $133 |
| Janssen Biotech, Inc. Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Jul 22, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Baton Rouge, LA · in-kind | $19.50 |
| Dendreon Pharmaceuticals LLC Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $4,550 |
| Dendreon Pharmaceuticals LLC Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $853 |
| Dendreon Pharmaceuticals LLC Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $592 |
| Astellas Pharma US Inc Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $1,950 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $918 |
| Astellas Pharma US Inc Jun 24, 2025 | Travel and Lodging Xtandi · Oncology · travel to Charleston, SC | $15.91 |
| Astellas Pharma US Inc Jun 21, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $3,900 |
| Astellas Pharma US Inc Jun 21, 2025 | Travel and Lodging Xtandi · Oncology · travel to Nashville, TN | $502 |
| Astellas Pharma US Inc Jun 21, 2025 | Travel and Lodging Xtandi · Oncology · travel to Nashville, TN | $367 |
| Janssen Biotech, Inc. Jun 3, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Baton Rouge, LA · in-kind | $560 |
| Janssen Biotech, Inc. May 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $416 |
| Janssen Biotech, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Janssen Biotech, Inc. May 21, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Oxford, MS | $91.00 |
| Avyxa Pharma, LLC May 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Avyxa Pharma, LLC May 17, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $795 |
| Avyxa Pharma, LLC May 17, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $415 |
| Avyxa Pharma, LLC May 17, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $47.92 |
| Dendreon Pharmaceuticals LLC Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $2,275 |
| Astellas Pharma US Inc Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) Xtandi · Oncology | $1,950 |
| Dendreon Pharmaceuticals LLC Mar 1, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $6,300 |
| Dendreon Pharmaceuticals LLC Mar 1, 2025 | Travel and Lodging PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER · travel to SEAL BEACH, CA | $671 |
| Dendreon Pharmaceuticals LLC Mar 1, 2025 | Travel and Lodging PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER · travel to SEAL BEACH, CA | $345 |
| Dendreon Pharmaceuticals LLC Mar 1, 2025 | Travel and Lodging PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER · travel to SEAL BEACH, CA | $185 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $47,594 in research payments for these studies, mostly to the institutions running them.
- A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176 - A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.